The association of neighborhood-level deprivation with glioblastoma outcomes: a single center cohort study - Top-Institutions - MDSpire

The association of neighborhood-level deprivation with glioblastoma outcomes: a single center cohort study

  • By

  • Yifei Sun

  • Dagoberto Estevez-Ordonez

  • Travis J. Atchley

  • Burt Nabors

  • James M. Markert

  • April 7, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-oncology
    • Cancer Epidemiology
    • Health Disparities Research

  • #2

    Dana-Farber Cancer Institute / Brigham and Women's Hospital
    Dana-Farber Cancer Institute / Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Neuro-oncology
    • Cancer Epidemiology
    • Health Equity Research

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neurosurgery
    • Neuro-oncology
    • Health Disparities

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-oncology
    • Cancer Health Disparities
    • Epidemiology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-oncology
    • Cancer Epidemiology
    • Health Disparities

Original Source(s)

The association of neighborhood-level deprivation with glioblastoma outcomes: a single center cohort study

  • by Yifei Sun, Dagoberto Estevez-Ordonez, Travis J. Atchley, Burt Nabors, James M. Markert

  • April 7, 2025

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease